About: Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti‐viral activity

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti‐viral activity Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti‐viral activity
Creator	Levy, Gary Gorczynski, Reginald He, William Rowe, Andrea Adamson, Gord Biessels, Pieter Fung, Laisum Ghanekar, Anand Levy, Adam Woods, Caroline Bell, David Mcgilvray, Ian Phillips, M Brookes, Steve Koscik, Cheryl Ma, Max Ng, Nancy Scrocchi, Louise
Source	Medline; PMC
abstract	Side effects of interferon–ribavirin combination therapy limit the sustained viral response achievable in hepatitis C virus (HCV) patients. Coupling ribavirin to macromolecular carriers that target the drug to the liver would reduce systemic complications. The aim of this study was to evaluate the efficacy of a hemoglobin–ribavirin conjugate (HRC 203) in murine hepatitis virus strain 3 (MHV‐3) induced viral hepatitis. HRC 203 had greater anti‐viral activity on both isolated hepatocytes and macrophages, whereas both ribavirin and HRC 203 inhibited production of the pro‐inflammatory cytokines interferon gamma (IFN‐γ) and tumor necrosis factor alpha (TNF‐α) by macrophages. In vivo, untreated MHV‐3–infected mice all developed clinical and biochemical signs of acute viral hepatitis and died by day 4 post infection. Livers recovered from untreated infected mice showed greater than 90% necrosis. In contrast, survival was enhanced in both ribavirin‐ and HRC 203–treated mice with a marked reduction in biochemical [ALT(max) 964 ± 128 IU/L (ribavirin); 848 ± 212 IU/L (HRC 203)] and histological evidence of hepatic necrosis (<10% in ribavirin/HRC 203 vs. 90% in untreated controls). Clinically, HRC 203–treated mice behaved normally, in contrast to ribavirin‐treated mice, which developed lethargy and abnormal fur texture. In conclusion, targeted delivery of ribavirin to the liver alters the course of MHV‐3 infection as demonstrated by prolonged survival, improved behavior, and reduced signs of histologically evident disease, as well as inhibition of viral replication and production of inflammatory cytokines in vitro. (Hepatology 2006;43:581–591.)
has issue date	2006-02-22(xsd:dateTime)
bibo:doi	10.1002/hep.21072
bibo:pmid	16496340
has license	no-cc
sha1sum (hex)	641e526ffd14d01050c4631a6b8aec5027e97f8b
schema:url	https://doi.org/10.1002/hep.21072
resource representing a document's title	Targeted delivery of ribavirin improves outcome of murine viral fulminant hepatitis via enhanced anti‐viral activity
has PubMed Central identifier	PMC7165489
has PubMed identifier	16496340
schema:publication	Hepatology
resource representing a document's body	covid:641e526ffd14d01050c4631a6b8aec5027e97f8b#body_text
is schema:about of	named entity 'liver' named entity 'Viral' named entity 'SYSTEMIC' named entity 'complications' named entity 'HCV' named entity 'tumor necrosis factor alpha' named entity 'ribavirin' named entity 'ribavirin' named entity 'ribavirin' named entity 'body weight' named entity 'scintillation counter' named entity 'ribavirin' named entity 'haptoglobin' named entity 'EDTA' named entity 'hemolytic' named entity 'aim' named entity 'hepatitis C virus' named entity 'ribavirin' named entity 'HCV' named entity 'peritoneal' named entity 'hepatocytes' named entity 'fluorescein' named entity 'serum' named entity 'infection' named entity 'liver transplantation' named entity 'histologically' named entity 'macrophages' named entity 'fibrin' named entity 'liver failure' named entity 'PBS' named entity 'conjugated' named entity 'hepatocytes' named entity 'macrophage' named entity 'conjugated' named entity 'acute hepatitis' named entity 'fibrin' named entity 'conjugated' named entity 'Hepatocytes' named entity 'ribavirin' named entity 'mmol' named entity 'blood urea nitrogen' named entity 'mice' named entity 'mice' named entity 'ribavirin' named entity 'lysosomal enzyme' named entity 'ribavirin' named entity 'viral replication' named entity 'mice' named entity 'mice' named entity 'endothelial cells' named entity 'haptoglobin' named entity 'phosphorylated' named entity 'ribavirin' named entity 'mouse model' named entity 'macrophage' named entity 'macrophages' named entity 'Blood Analysis' named entity 'tail vein' named entity 'positive-stranded' named entity 'interferon' named entity 'hepatic' named entity 'viral titers' named entity 'molar' named entity 'infection'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software